Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biodistribution and Antitumour Activity of the Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07214961 is registered in ClinicalTrials.gov with ARTBIO Inc. as lead sponsor.

NCT NCT07214961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biodistribution and Antitumour Activity of the Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer
Lead sponsor
ARTBIO Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 3, 2025
Completion date
November 3, 2028
Enrollment
80 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castrate resistant prostate cancer (mcrpc), prostate cancer (crpc)